Ulcerative colitis (UC) is a chronic gut inflammatory condition affecting the colon in humans. This study uses human samples as well as a mouse model of colitis induced by a chemical, DSS, to ...

Binghamton University will play a key role in a federal grant of up to $42.8 million to develop an implantable device that acts as a living pharmacy to treat inflammatory diseases. Mayo Clinic is the ...

Direct costs associated with IBD include ambulatory visits to gastroenterologists, emergency department visits, admissions ...

Mirikizumab, a drug currently approved by the Food and Drug Administration (FDA) for the treatment of ulcerative colitis, ...

Q3 2024 Earnings Call Transcript October 30, 2024 AbbVie Inc. beats earnings expectations. Reported EPS is $3, expectations ...

It’s a new era for AbbVie. For the first time in years, the company has a new top sales driver as Skyrizi has overtaken Humira in quarterly sales. | After several quarters of creeping up on Humira, ...

Prademagene zamikeracel (pz-cel) could be a new treatment for rare genetic disease recessive dystrophic epidermolysis bullosa (RDEB).

Eli Lilly and Johnson & Johnson are seeking label expansions for Omvoh and Tremfya, respectively, in Crohn’s disease ...

Crohn’s disease is a type of inflammatory bowel disease (IBD) that involves periods of remission and flares. Symptoms can ...

Eli Lilly announced that mirikizumab achieved long-term remission in Phase 3 IBD studies, showing promise for ulcerative ...

Eli Lilly (LLY) announced results from two, multi-year, Phase 3 studies that showed patients treated with mirikizumab sustained stable, ...